JOHANNESBURG, SOUTH AFRICA--(Marketwire - January 05, 2011) - www.wallstreetequityresearch.com gives shareholders valuable insight on biotechnology stocks Advanced Cell Technology Inc. (OTCBB: ACTC) and Bioheart Inc. (OTCBB: BHRT). Sign up today at www.wallstreetequityresearch.com to receive free research reports on these equities.
As baby boomers continue their march into old age, many companies in the Biotechnology Industry are focusing their efforts on the treatment of the dysfunctions and diseases afflicting the aged. The treatment of heart attacks and macular degeneration, a cause of vision loss, are two such areas that have been receiving attention as of late. With new research into the applications of stem cells, companies in the industry are racing to be the first to successfully apply them in the treatment of various ailments. Visit us at http://www.wallstreetequityresearch.com/ to understand the catalysts and forces driving or affecting the biotechnology industry in today's economic environment.
www.wallstreetequityresearch.com is a specialized website where investors can have specific access to free reports biotechnology industry; traders looking for analyst opinions on Advanced Cell Technology Inc., Bioheart Inc. and other companies in this industry are welcomed to sign up for a free one year membership at http://www.wallstreetequityresearch.com/.
Advanced Cell Technology Inc., whose business revolves around the use of stem cells to treat vision loss, has been performing well as of late. The company has recently received $25 million in funding, and is hoping to use it to bring a few of their projects through clinical trials. The company has also recently been approved by the FDA to start clinical trials on patients with dry AMD, a form of macular degeneration that can lead to loss of vision and blindness. Traders can get direct and free access to today's full report on Advanced Cell Technology Inc. by signing up at http://wallstreetequityresearch.com/January052011AdvancedCellTechnologyInc.(ACTC.OB)050111.php.
Fellow stem cell biotech company Bioheart Inc. is not faring as well. The company, which is researching the use of stems cells in the treatment of heart attack patients, has recently suspended their clinical trials due to a funding dispute. Of concern to those funding the trial is the question of patient safety. Traders can have complimentary access to today's complete research report on Bioheart Inc. by signing up at http://wallstreetequityresearch.com/January052011BioheartInc.(BHRT.OB)050111.php.
About Wall Street Equity Research:
Wall Street Equity Research looks to bring simplicity and highly sophisticated research to an ever-changing investing environment. Wall Street Equity Research has been partnering with a number of North American and Emerging Economies analysts to bring you the best of both continents in terms of market analysis and analytical opinions.
